Gyroscope Therapeutics Announces Research Collaboration Agreement with Children’s Medical Research Institute to Develop Novel Gene Therapy Capsids

LONDON–(BUSINESS WIRE)–Gyroscope Therapeutics Holdings plc (“Gyroscope”), a clinical-stage gene therapy company focused on the treatment of eye diseases, today announced that it has entered into a research collaboration with the Children’s Medical Research Institute ( “CMRI”) in Australia to develop next-generation clinical capsids, the protein shells of viral vectors used to deliver gene therapies.

A team of researchers from CMRI and Gyroscope will collaborate on the design and screening of capsid libraries to identify novel capsids for enhanced delivery of ocular gene therapies. Under the agreement, Gyroscope has an option to obtain an exclusive license for ocular use of capsids developed by the partnership. The CMRI team is led by associate professor Leszek Lisowski, Ph.D., MBA, a recognized expert in viral vector-based gene therapy, vectorology and genotoxicity, with more than 15 years of experience in capsid generation and discovery.

“Capsids are one of the most critical components of a gene therapy, but there are some limitations with the capsids available today,” said Jane Hughes, Ph.D., Chief Scientific Officer, Gyroscope. “We are excited to partner with associate professor Lisowksi and the team at CMRI to develop next-generation capsids that support our goal of developing a pipeline of differentiated ocular gene therapies that have the potential to be delivered in the convenience of a doctor’s office.”

“Gene therapies are being studied in many eye diseases, and capsids play an important role in maximizing the potential benefit of these therapies for patients,” said Dr. Lisowski. “We look forward to working with the Gyroscope team to identify novel capsids that may improve the current standard of gene therapies for the treatment of eye disease.”

About Gyroscope: Vision for Life

Gyroscope Therapeutics is a clinical-stage gene therapy company developing gene therapy beyond rare diseases to treat eye diseases that cause vision loss and blindness. Our investigational lead gene therapy, GT005, is currently being evaluated in Phase II clinical trials for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD), a leading cause of blindness. GT005 has received Fast Track designation from the US Food and Drug Administration for the treatment of people with GA.

Backed by leading life science investors, Gyroscope has built a global organization that combines discovery, research, drug development, a manufacturing platform and surgical delivery capabilities. With headquarters in London and locations in Philadelphia and San Francisco, our mission is to preserve vision and combat the devastating effects of blindness.

For more information visit: and follow us on Twitter (@GyroscopeTx) and on LinkedIn.

About Children’s Medical Research Institute

Children’s Medical Research Institute (CMRI) pioneered microsurgery, immunizations against fatal childhood diseases and care for premature babies, all of which have improved the lives of countless Australian children over the past 61 years. Today, the CMRI is an independent institute and the site of leading research in cancer, neurobiology, embryology, proteogenomics and gene therapy. CMRI is affiliated with the University of Sydney and is a founding member of Luminesce Alliance and the Westmead Research Hub.

The scientists of CMRI enter into research collaborations worldwide. CMRI is also home to high-tech research facilities available to researchers and organizations across Australia and internationally. It operates CellBank Australia™, Australia’s only national repository of cell cultures; is home to advanced gene therapy and gene engineering facilities – creating treatments of the future. In addition, the CMRI is home to two Australian Cancer Research Foundation Centres, including the ACRF Telomere Analysis Center and ProCan®, which together aim to significantly advance understanding of the biology of cancer and produce technologies to diagnose and treat all types of cancer. improve.

CMRI’s achievements are made possible through a network of dedicated community supporters and through the iconic Jeans for Genes® fundraising campaign. For more information, visit:

Comments are closed.